

## IDENTIFYING PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (PSMA-POSITIVE MCRPC)

### INSTRUCTIONS

OncoEMR has reporting tools available to help identify patients with PSMA-positive MCRPC and assess clinical factors of these patients.

**Workflow:** Track and manage patients requiring Radioligand Therapy.

#### 1. Configuration Steps for IT Analysts:

- Set up dynamic dashboards to monitor active referrals and order statuses
- Configure filters to display only:
  - Active orders
  - Radioligand therapy-specific referrals

**Additional Notes:** Use OncoEMR's analytics module to generate real-time reports and ensure data is up-to-date.

#### IT Analyst Notes:

- Regularly review system configurations to align with organizational policies
- Provide ongoing training to users to maximize system efficiency
- Monitor workflow performance and gather feedback for continuous improvement

### LIMITATIONS AND NOTES

EHR, electronic health record; EMR, electronic medical record; HIT, health information technology; IS, information system; IT, information technology.

Novartis is not responsible for the implementation, testing, and ongoing operation of any EHR tools. If you have any questions pertaining to the use of these guides, please refer to your internal IT/IS department. These tools are not designed for, and have not been demonstrated to meet, any accreditation requirements. The instructions included in this brochure are applicable to the OncoEMR platform and are not guaranteed to work for any other software platforms.

OncoEMR® is a registered trademark of Flatiron Health, Inc.

For more information on how the Novartis HIT Team can collaborate with your organization to identify shared priorities please email: [HIT.Novartis@novartis.com](mailto:HIT.Novartis@novartis.com)